Chemotherapy for Non-Small Cell Lung Cancer in the Intensive Care Unit.


Journal

Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651

Informations de publication

Date de publication:
2021
Historique:
received: 28 11 2020
revised: 18 12 2020
accepted: 19 12 2020
pubmed: 1 1 2021
medline: 1 1 2022
entrez: 31 12 2020
Statut: ppublish

Résumé

patients with non-small-cell lung cancer (NSCLC) admitted to the intensive care unit have poor prognosis. There is limited data on cytotoxic chemotherapy in this setting. The standard of care for these patients is usually best supportive care. 60-year-old previously healthy female was admitted to the ICU with newly diagnosed mucinous adenocarcinoma of the lung. She received cisplatin and pemetrexed while intubated and mechanically ventilated. She was extubated a week later and discharged home after achieving an excellent radiographic and clinical response. in select patients with NSCLC admitted to the ICU due to complications from their malignancy, a trial of cytotoxic chemotherapy may be reasonable. To our knowledge, this is the first case of mucinous NSCLC treated in the ICU.

Sections du résumé

BACKGROUND
patients with non-small-cell lung cancer (NSCLC) admitted to the intensive care unit have poor prognosis. There is limited data on cytotoxic chemotherapy in this setting. The standard of care for these patients is usually best supportive care.
CASE
60-year-old previously healthy female was admitted to the ICU with newly diagnosed mucinous adenocarcinoma of the lung. She received cisplatin and pemetrexed while intubated and mechanically ventilated. She was extubated a week later and discharged home after achieving an excellent radiographic and clinical response.
DISCUSSION
in select patients with NSCLC admitted to the ICU due to complications from their malignancy, a trial of cytotoxic chemotherapy may be reasonable. To our knowledge, this is the first case of mucinous NSCLC treated in the ICU.

Identifiants

pubmed: 33383487
pii: S2468-2942(20)30129-5
doi: 10.1016/j.ctarc.2020.100294
pii:
doi:

Substances chimiques

Pemetrexed 04Q9AIZ7NO
Cisplatin Q20Q21Q62J

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100294

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Abdullah Nasser (A)

Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Michael Hartwick (M)

Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Kwadwo Kyeremanteng (K)

Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Paul Wheatley-Price (P)

Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. Electronic address: pwheatleyprice@toh.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH